Clinical Trial

Alessa is currently conducting their first in-man clinical study of Biolen™ PC, a minimally-invasive, drug delivery implantable system with patients with prostate cancer. Biolen PC is designed to administer anti-androgen drugs to the tumor in the prostate through a sustained, localized system – without systemic exposure.

The primary objectives of the study are to assess the safety and patient tolerance of Biolen PC. The study is being conducted at several clinical institutions in Australia and New Zealand. We are looking to recruit men over the age of 35 who:

Have biopsy confirmed prostate cancer – Gleason score 3+4 or higher
Are scheduled to undergo surgery to remove the prostate
Are willing and able to undergo MRI follow-up imaging

There are additional inclusion and exclusion criteria. For more details about the study, please go to https://clinicaltrials.gov/ct2/show/NCT04284761 or contact CP001@alessatherapeutics.com.

Alessa will also be evaluating whether the same approach can be used to treat benign prostatic hyperplasia.